Theravance Biopharma
TBPH
108 hedge funds and large institutions have $882M invested in Theravance Biopharma in 2021 Q2 according to their latest regulatory filings, with 20 funds opening new positions, 41 increasing their positions, 26 reducing their positions, and 19 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
73% more call options, than puts
Call options by funds: $1.45M | Put options by funds: $838K
58% more repeat investments, than reductions
Existing positions increased: 41 | Existing positions reduced: 26
2.32% more ownership
Funds ownership: 82.09% → 84.41% (+2.3%)
5% more first-time investments, than exits
New positions opened: 20 | Existing positions closed: 19
1% more funds holding
Funds holding: 107 → 108 (+1)
19% less capital invested
Capital invested by funds: $1.09B → $882M (-$210M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MS
Maven Securities
St Helier,
Jersey
|
+$25.2M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$23.7M |
| 3 |
BG
Baupost Group
Boston,
Massachusetts
|
+$22.1M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
+$19.9M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
-$31.1M |
| 2 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
-$4.69M |
| 3 |
UBS Group
Zurich,
Switzerland
|
-$4.11M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$3.14M |
| 5 |
BlackRock
New York
|
-$2.13M |
TBPH Hedge Fund Activity: Q2 2021 in Review
108 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Theravance Biopharma (TBPH) for Q2 2021, worth a combined $882M — down 19% from $1.09B a quarter earlier.
Buyers outnumbered sellers: 20 funds opened new TBPH positions and 19 closed out — a net gain of 1 holder — while 41 added to existing stakes and 26 trimmed.
The largest buyer was Maven Securities, opening a new position worth an estimated $25.2M. The largest seller was OrbiMed, cutting an estimated $31.1M.
- 108 institutional investors held Theravance Biopharma (TBPH) as of Q2 2021, up from 107 in Q1 2021.
- Funds reported $882M of Theravance Biopharma stock for Q2 2021, down 19% quarter-over-quarter.
- 20 funds opened new Theravance Biopharma positions in Q2 2021 and 19 closed out, a net change of +1 holder.
- The largest Theravance Biopharma buyer in Q2 2021 was Maven Securities, an estimated $25.2M added.
- The largest Theravance Biopharma seller in Q2 2021 was OrbiMed, an estimated $31.1M sold.
Based on aggregated 13F filings for Q2 2021.